Fintech PR
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
FinancialNewsMedia.com News Commentary
PALM BEACH, FL, Oct. 17, 2023 /PRNewswire/ — Multiple myeloma is a type of cancer that affects plasma cells, which are a type of white blood cell that produces antibodies to fight infections. The US multiple myeloma therapeutics market is a growing market due to the increasing prevalence of multiple myeloma and the development of new therapies. The growth of the market is driven by factors such as an aging population, increasing prevalence of multiple myeloma, and advancements in the development of new therapies. The introduction of new therapies such as immunomodulatory drugs (IMiDs) and proteasome inhibitors has revolutionized the treatment of multiple myeloma. A report from Insights10 projected that the U.S. Multiple Myeloma Therapeutics Market was valued at $3.5 Billion in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 2.5% from 2022 to 2030 and will reach $4.26 Billion in 2030. Active companies in the markets this week include: Telo Genomics Corp. (OTCQB: TDSGF) (TSXV: TELO), Guardant Health, Inc. (NASDAQ: GH), Natera, Inc. (NASDAQ: NTRA), Quest Diagnostics Incorporated (NYSE: DGX), NeoGenomics, Inc. (NASDAQ: NEO).
The report said: “The cost of multiple myeloma therapies is high, and the cost of newer therapies such as monoclonal antibodies and CAR T-cell therapy is even higher. This limits the affordability of these therapies for many patients, leading to barriers in access to treatment. The treatment of multiple myeloma is complex and often requires a combination of therapies, including chemotherapy, radiation therapy, stem cell transplantation, and targeted therapies. This complexity can lead to challenges in treatment planning and management, as well as potential side effects and complications. Many multiple myeloma therapies have adverse side effects, including anemia, fatigue, neuropathy, and gastrointestinal problems. These side effects can impact the quality of life for patients and limit the effectiveness of therapies. Despite significant advancements in the development of new therapies, some patients may not respond to treatment or may develop resistance to therapies. This limits the efficacy of existing therapies and highlights the need for continued research and development of new treatments. The US multiple myeloma therapeutics market is highly regulated, with strict requirements for drug approval and pricing. This can lead to delays in the approval of new therapies and challenges in pricing and reimbursement for existing therapies.”
Telo Genomics Corp. (OTCQB: TDSGF) (TSXV: TELO) BREAKING NEWS: Telo Genomics Announces Clinical Launch of Non-Invasive Cancer Diagnostic, TeloViewSMM – An Important Commercial Milestone Achieved – TeloView Analyses Telomeres to Accurately Predict and Characterize Multiple Myeloma – Telo Genomics Corp. (the “Company” or “Telo”) today announced the launch of its TeloViewSMM to clinicians in the United States.
Combining molecular biology and artificial intelligence, the diagnostic platform performs industry leading 6-factor quantitative analysis of 3D telomeres, the protective end caps of chromosomes.
TeloView has the potential to characterize multiple cancers, identify their current level of genomic instability and therefore predict their progression.
The Company’s initial clinical launch will focus on testing for “Smoldering Multiple Myeloma (SMM)” the precursor for Multiple Myeloma, a blood-based bone marrow cancer. Approximately 50% of patients with SMM will develop full Multiple Myeloma.
The test is available for physicians to order under the SMART (Smoldering Multiple myeloma Assessment of Risk for Transformation) protocol, an observational study intended for oncology/hematology physicians and their staff in the U.S., to gain experience ordering and utilizing the TeloViewSMM assay. SMART follows a positive industry trend toward introducing novel molecular testing tools in an observational construct to efficiently gather information and feedback from clinicians and their teams.
“The commercial launch of our flagship TeloView platform is a major milestone for our Company” stated Telo Genomics’ CEO Kris Weinberg. “I am extremely proud of our entire team who have put forth a tremendous effort over many years in the development of our platform. Our presentations at this year’s International Myeloma Society (“IMS”) annual meeting and the American Society of Clinical Oncology’s annual meeting were received very positively and have generated many leads for our new assay. We are also very active in discussions with platform partners and in the development of new tests in additional applications.”
While the initial launch of TeloViewSMM will be conducted as a single-site CLIA (Clinical Laboratory Improvement Amendments) model, commercial-scale delivery of testing will be accomplished in partnership with large reference labs where FISH and microscopy resources are available and scalable. The company is also developing products and use cases for the biopharma and CRO segment and has an active business development pipeline focused on CDx opportunities and contract research. CONTINUED… Read this full press release and more news for Telo Genomics at: https://www.financialnewsmedia.com/news-telo/
Other recent developments in the markets of note include:
Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, recently announced that Geisinger Health Plan now offers coverage for the Guardant Reveal™ minimal residual disease (MRD) test. Guardant Reveal is a blood test that detects circulating tumor DNA (ctDNA) in blood after treatment, including surgery, to help oncologists identify cancer patients with residual or recurring disease who may benefit most from adjuvant therapy or surveillance. It is the first blood-only liquid biopsy test commercially available for MRD testing.
Geisinger is providing coverage for the Guardant Reveal test for individuals with stage II or III colorectal cancer after curative treatment (including surgery) to inform physician decisions about post-treatment therapy and to monitor for disease progression, recurrence or relapse. The frequency of testing covered is aligned with monitoring guidelines established by the National Comprehensive Cancer Network for colorectal cancer. It includes the initial ctDNA test 4 to 6 weeks after surgery (or 2 to 4 weeks after completion of systemic therapy) and thereafter every 3 to 6 months for the first two years, and every 6 to 12 months for the following 3 years.
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, recently announced it will present new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, at the 2023 European Society for Medical Oncology (ESMO) Congress, taking place Oct. 20-24 in Madrid, Spain.
Natera and its collaborators will present MRD data in a total of seven abstracts, including a mini-oral and several poster presentations. The mini-oral presentation will feature an updated analysis of more than 2,000 patients from the GALAXY observational arm of the CIRCULATE-Japan trial, one of the largest and most comprehensive prospective studies of MRD testing in resectable colorectal cancer (CRC). Other presentations will highlight new Signatera data in rectal cancer, appendiceal adenocarcinoma, hepatocellular carcinoma, renal cell carcinoma, and other solid tumors.
Quest Diagnostics Incorporated (NYSE: DGX), the world’s leading provider of diagnostic information services, recently announced that it will report third quarter 2023 financial results on Tuesday, October 24, 2023, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Timeon that day.
The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, using the passcode: “7895081.” The earnings release and live webcast will be posted on www.QuestDiagnostics.com/investor. The company suggests participants dial in approximately 10 minutes before the call.
A replay of the call may be accessed online at www.QuestDiagnostics.com/investor or by phone at 800-945-5759 for domestic callers or 203-369-3502 for international callers; no passcode is required. Telephone replays will be available from approximately 10:30 a.m. Eastern Time on October 24, 2023 until midnight Eastern Time on November 7, 2023.
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, recently announced that the Molecular Diagnostics Services Program (MolDx) has conveyed coverage for the RaDaR® assay, a personalized liquid biopsy for minimal residual disease (MRD) and recurrence detection.
Following this decision, effective as of March 24, 2023, the RaDaR assay is now covered for fee-for-service Medicare patients within the United States with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. The coverage includes patients with a personal history of high-risk stage II/III HR+/HER2- breast cancer, five or more years from diagnosis who presently do not have evidence of disease.
DISCLAIMER: FN Media Group LLC (FNM), which owns and operates FinancialNewsMedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM was compensated forty six hundred dollars for news coverage of the current press releases issued by Telo Genomics Corp. by a non-affiliated third party. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.
Contact Information:
Media Contact email: [email protected] – +1(561)325-8757
View original content:https://www.prnewswire.co.uk/news-releases/multiple-myeloma-therapeutics-market-expected-to-reach-4-26-billion-in-2030–301958687.html
Fintech PR
GCash enables seamless linkage of Overseas Filipino remittances with UK and EU bank cash in
MANILA, Philippines, Nov. 26, 2024 /PRNewswire/ — GCash, the Philippines’ leading finance super app and largest cashless ecosystem, further expands its presence overseas, particularly in the United Kingdom and Europe, through the new UK/EU Bank Cash In feature, revolutionizing remittance for around two million Filipinos in Europe.
Starting in November, overseas Filipinos in the UK and Europe will be able to seamlessly link their international bank accounts to GCash, making it easier and more convenient to send remittances to the Philippines.
Previously, sending money from the UK and Europe to the Philippines has been a complex and time-consuming process, often involving expensive fees and multiple intermediaries. With the new feature, Filipinos can enjoy lower fees and faster transaction times when sending money home, as well as competitive exchange rates and real-time access to funds.
“Many Filipinos have chosen Europe and the United Kingdom as their home. GCash hopes to provide their needs and help them connect with their loved ones, as a trusted digital finance partner made for Filipinos, by Filipinos,” said Paul Albano, GCash International General Manager.
Floris de Kort, CEO of Thunes, added, “We are expanding our collaboration with GCash, a long-standing valued Member of our Direct Global Network, to transform digital wallet top-ups. Through Thunes’ Direct Global Network, we are now delivering an instant top-up service that simplifies cross-border transactions. Our alliance with GCash is a testament to our passion for innovation, the versatility of our proprietary network, and our dedication to financial inclusion through money movement around the world.”
Through its vision of making ‘Finance for All’ a reality for its users around the world, GCash has recently become the Philippines’ first and only $5 billion unicorn. With its relentless push for financial inclusion and strong growth prospects, it recently gained new investments from Japan’s largest banking group Mitsubishi UFJ Financial Group (MUFG), and Ayala Corporation one of the Philippines’ biggest and most enduring conglomerates.
“At GCash, we prioritize finance for all Filipinos whether they are in the Philippines or abroad. We know our countrymen in Europe and the UK work hard to provide for their families back home,” says Albano. “We want to make their lives easier by looking for more convenient ways to help them send money back to their families.”
About GCash
GCash is the Philippines’ #1 Finance Super App and Largest Cashless Ecosystem. Through the GCash App, users can easily purchase prepaid airtime; pay bills via partner billers nationwide; send and receive money anywhere in the Philippines, even to other bank accounts; purchase from over 6 million partner merchants and social sellers; and get access to savings, credit, loans, insurance and invest money, and so much more, all at the convenience of their smartphones. Its mobile wallet operations are handled by G-Xchange, Inc. (GXI), a wholly-owned subsidiary of Mynt, the first and only $5 billion unicorn in the Philippines.
About Thunes:
Thunes is the Smart Superhighway to move money around the world. Thunes’ proprietary Direct Global Network allows Members to make payments in real-time in over 130 countries and more than 80 currencies. Thunes’ Network connects directly to over 7 billion mobile wallets and bank accounts worldwide, as well as 15 billion cards via more than 320 different payment methods, such as GCash, M-Pesa, Airtel, MTN, Orange, JazzCash, Easypaisa, AliPay, WeChat Pay and many more. Thunes’ Direct Global Network differentiates itself through its worldwide reach, in-house SmartX Treasury System and Fortress Compliance Platform, ensuring Members of the Network receive unrivaled speed, control, visibility, protection, and cost efficiencies when making real-time payments, globally. Members of Thunes’ Direct Global Network include gig economy giants like Uber and Deliveroo, super-apps like Grab and WeChat, MTOs, fintechs, PSPs and banks. Headquartered in Singapore, Thunes has offices in 15 locations, including Abidjan, Barcelona, Beijing, Dubai, Hong Kong, Johannesburg, London, Manila, Nairobi, Paris, Riyadh, San Francisco, Sao Paulo and Shanghai. For more information, visit: https://www.thunes.com/
Photo – https://mma.prnewswire.com/media/2567632/GCash_x_Thunes_2.jpg
View original content:https://www.prnewswire.co.uk/news-releases/gcash-enables-seamless-linkage-of-overseas-filipino-remittances-with-uk-and-eu-bank-cash-in-302316421.html
BEIJING, Nov. 26, 2024 /PRNewswire/ — The renowned Italian luggage maker BRIC’S in partnership with BranDNA are thrilled to announce the opening of BRIC’S first China brick-and-mortar shop in the bustling Wangfujing shopping district of Beijing.
This strategic entry follows BRIC’S remarkable success in key Asian markets such as Japan and Korea, marking a significant milestone in its international expansion journey.
Founded in 1952, BRIC’S has become synonymous with luxury and elegance, famous for its premium leather craftsmanship and the meticulous artistry that goes into every piece of luggage, seamlessly blending tradition with innovation and function.
The newly opened BRIC’S store at Dong An Rui Jin in Beijing offers a diverse range of its signature collections, including the BELLAGIO, FIRENZE, LIFE, and X-COLLECTION tailored to discerning traveler needs.
“We see great potential in the Chinese market, especially as travel rebounds post-pandemic,” stated Attilio Briccola, CEO of BRIC’S. “This partnership with BranDNA is pivotal in ensuring that our brand is strategically positioned for success. BranDNA’s deep industry expertise and robust network will help us present our elegant creations to a whole new audience.”
China’s travel sector is booming, with outbound trips expected to reach 130 million this year and domestic travel up by 14.3% in the first half of 2024, per the Ministry of Culture and Tourism. This surge presents a key opportunity for BRIC’S.
James Chen, CEO of BranDNA, shared, “We are excited to satisfy the burgeoning demand of today’s travelers who seek both style and utility in their travel accessories. With BRIC’S, we aim to set a new standard in the Chinese luggage market.”
With over 20 years of brand management experience in China, BranDNA manages strong portfolio of fashion and lifestyle brands, including 7 For All Mankind, United Arrows, Pink House, BCBGMAXAZRIA, Ben Sherman, Body Glove, Borghese and many others.
Visit the new BRIC’S location at Dong An Rui Jin, Store F1-11, No. 138 Wangfujing Street, Dongcheng District, Beijing, and experience the art of Italian craftsmanship.
About BranDNA
With a comprehensive functional service, including China entry strategy, merchandising, retail management, business development network marketing, and more, BranDNA offers a one-stop solution and a safer and efficient road for brands entering China and Southeast Asia.
Discover more about BranDNA at www.brandna.net or connect via LinkedIn at BranDNA.
About BRIC’S
BRIC’S is a luxury Italian luggage brand known worldwide for its exceptionally designed luggage including trolleys, duffles, handbags, briefcases, and other leather and nylon goods. BRIC’S collections have always been characterized by constant development, where research and Heritage, innovation and tradition, functionality, and elegance are intertwined and balanced with skilled craft, advanced technology, and interpretation of new trends, creating a perfect fusion between shape, function, and design. Today, BRIC’S reflects timeless elegance typical of its province, Lake Como, harmoniously blending with the urban and cosmopolitan style of Milan – the city that hosts its most important Flagship Store in the Galleria Vittorio Emanuele.
For more information: www.brics.it | IG @bricsmilano | FB @bricsmilano
View original content:https://www.prnewswire.co.uk/news-releases/brics-partners-with-brandna-to-launch-first-brick-and-mortar-store-in-mainland-china-302316389.html
Fintech PR
Hinojosa obtains a new EcoVadis gold medal with a score greater than 97% of the companies evaluated
- The company has certified the sustainability of its business management with EcoVadis, receiving the third consecutive gold medal
- With 78 points out of 100, Hinojosa has received its best score to date, mostly due to improvements in key areas such as environment, labour practices and human rights
VALENCIA, Spain, Nov. 26, 2024 /PRNewswire/ — Hinojosa Packaging Group has been awarded the EcoVadis gold medal for the third consecutive year, achieving with 78 points out of 100 its highest score to date and being placed in the 97th percentile of the best rated companies. The company has experienced sustained growth since has started in 2020 to certify management and positive impact on sustainability, within this internationally recognised platform.
The EcoVadis evaluation covers a wide range of non-financial management systems, including impact on issues such as environment, labour practices and human rights, ethics and sustainable procurement. Both in environmental area and labour practices & human rights’ area, the company has improved its previous scores by 10 points, reaching, respectively, 90 and 80. Progress in these two areas has enabled Hinojosa to further improve this year the overall score and position itself in the top 3% of all companies.
The improvement in the environmental area is due, among other things, to the validation of the emissions reduction targets and to achieving the Net-Zero Standard in 2050, as part of the SBTi (Science Based Target initiative). Some of the company’s commitments in this area include achieving a 60% reduction in Scope 1 and 2 emissions and a 42% reduction in Scope 3 emissions by 2030, in addition to using 100% of its electricity from renewable sources.
Adding to these commitments to the future, Hinojosa continues to work on a daily basis to ensure that its constant, steady and sustainable growth is guaranteed accordingly to circular economy’s principle. During 2023, the company reduced emissions by 16% compared to the previous year. This outstanding reduction of carbon footprint was also followed by a waste recovery rate over 95% and a 7% increase in the energy used for production from renewable sources, reaching 71% of the total energy used.
Hinojosa’s efforts to generate a positive impact in labour practices and human rights has also been recognised by EcoVadis. The expansion and consolidation of its FP Dual program or the creation of Hinojosa Cathedra together with Universitat Politècnica de València are some of the most relevant initiatives. In addition, the commitment of all company’s employees to comply with the MSH (Hinojosa Safety Model) has led to an almost fifty percent reduction in global occupational injuries.
EcoVadis corporate sustainability ratings assess each company based on its size, location and business area. More than 90,000 companies are rated internationally, receiving scores between 0 and 100 and in case their performance excels, EcoVadis will grant medals. After winning a bronze medal in 2020 and a silver medal in 2021, Hinojosa has now three consecutive gold medals in 2022, 2023 and 2024. Furthermore, thanks to this assessment, the company has received guidance on its strengths and 22 areas for improvement, which allows Hinojosa to focus on sustainability efforts and to develop action plans to improve performance.
About Hinojosa Packaging Group
Hinojosa is a leading company in the design and manufacture of sustainable packaging solutions. With more than 75 years of history, its model is based on the principles of the circular economy.
Thanks to permanent innovation, customer orientation and the pursuit of excellence, the Group has continued to grow, experiencing a significant boost in recent years with its commitment to internationalisation. Today it has 2900 employees and 24 production plants located in Spain, Portugal, France and Italy, combining the strength of a global group with proximity to the territory.
Hinojosa’s commitment – and performance – is to generate a positive impact where it operates, contributing to a greater common well-being. Because it is not only about making the best packaging, but taking care of everything around you.
Photo: https://mma.prnewswire.com/media/2566591/Hinojosa_Packaging_Group.jpg
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/hinojosa-obtains-a-new-ecovadis-gold-medal-with-a-score-greater-than-97-of-the-companies-evaluated-302315430.html
-
Fintech6 days agoFintech Pulse: Industry Updates, Innovations, and Strategic Moves
-
Fintech5 days agoFintech Pulse: Daily Industry Brief – A Dive into Today’s Emerging Trends and Innovations
-
Fintech PR5 days agoTAILG Represents the Industry at COP29, Advancing South-South Cooperation with Low-Carbon Solutions
-
Fintech PR6 days agoROLLER Releases 2025 Attractions Industry Benchmark Report, Unveiling Key Trends and Revenue Strategies
-
Fintech7 days agoFintech Pulse: Milestones, Partnerships, and Transformations in Fintech
-
Fintech PR4 days agoAlkira Ranked 25th Fastest-Growing Company in North America and 6th in the Bay Area on the 2024 Deloitte Technology Fast 500™
-
Fintech PR6 days agoThe CfC St. Moritz Announces New Speakers from BlackRock, Binance, Bpifrance, Temasek, PayPal, and More for Upcoming 2025 Conference
-
Fintech PR4 days agoCorinex Ranked Number 331 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™